Drug- and chemical-induced cholestasis

Clinics in Liver Disease

Volumn 8, Issue 1, 2004, Pages 95-132

  Mohi Ud Din, Raja ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; AMITRIPTYLINE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; APRINDINE; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CARBUTAMIDE; CHLOROTHIAZIDE; CHLORPROMAZINE; CIMETIDINE; CLINDAMYCIN; COTRIMOXAZOLE; CYAMEMAZINE; CYPROHEPTADINE; ERYTHROMYCIN; HALOPERIDOL; IBUPROFEN; IMIPRAMINE; ORGANOARSENIC DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PSYCHOTROPIC AGENT; TERFENADINE; TETRACYCLINE DERIVATIVE; TIABENDAZOLE; TROLEANDOMYCIN; UNINDEXED DRUG;

BILE DUCT INJURY; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; EXTRAHEPATIC BILE DUCT OBSTRUCTION; HUMAN; JAUNDICE; PRIMARY BILIARY CIRRHOSIS; REVIEW; SCLEROSING CHOLANGITIS;

CHOLESTASIS; HUMANS; PARENTERAL NUTRITION, TOTAL; PHARMACEUTICAL PREPARATIONS;

EID: 1642272235     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00124-7     Document Type: Review

References (213)

1. Lewis J.H., Zimmerman H.J. Drug-and chemical-induced cholestasis. Clin Liver Dis. 3:1999;433-464.
2. Zimmerman H.J. Drug-induced liver disease. Schiff E.R., Sorrell M.F., Maddrey W.C. Schiff's diseases of the liver. 1999;973-1064 Lippincott-Raven, Philadelphia.
3. Bohan A., Boyer J.L. Mechanisms of hepatotoxicity transport of drugs: implications for cholestatic drug reaction. Semin Liver Dis. 22:2002;123-136.
4. Trauner M., Meier P.J., Boyer J.L. Molecular pathogenesis of cholestasis. N Engl J Med. 339:1998;1217-1227.
5. Popper H., Schaffner F. Pathophysiology of cholestasis. Hum Pathol. 1:1970;1-24.
6. Zimmerman H.J. Intrahepatic cholestasis. Arch Intern Med. 139:1979;1038-1045.
7. Alonzo-Ruiz A., Calabozo M., Perez-Ruiz F.et al. Toxic oil syndrome. A long term follow up of a cohort of 332 patients. Medicine. 72:1993;283-295.
8. Hautekeete M.L., Brenard R., Harsmans Y.et al. Liver injury related to amoxicillin-clavulanic acid interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol. 22:1995;71-77.
9. Degott C., Feldman G., Larrey D.et al. Drug-induced prolonged cholestasis in adults. A histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 15:1992;244-251.
10. Green R.M., Crawford J.M. Hepatocellular cholestasis: pathology and histological outcome. Semin Liver Dis. 15:1995;372-389.
11. Ishak K.G., Irey N.H. Hepatic injury associated with phenothiazines. Arch Pathol. 93:1972;283-304.
12. Ishak K.G., Zimmerman H.J. Hepatotoxic effectsof the anabolic/androgenic steroids. Semin Liver Dis. 7:1987;230-236.
13. Zimmerman H.J., Lewis J.H. Drug-induced cholestasis. Med Toxicol. 2:1987;112-160.
14. Moradpour D., Altofer J., Flury R.et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology. 20:1994;1437-1441.
15. Fonquernie L., Girard P.M., Cardon B.et al. Hemolytic jaundice related to ingestion of indinavir. Presse Med. 26:1997;1578.
16. Perry M.C. Chemotherapeutic agents and hepatotoxicity. Semin Oncol. 19:1992;551-565.
17. Yamada S., Takehara K., Arai T.et al. Immunocytochemical studies on cholestatic factor in human liver with or without cholestasis. Liver. 10:1990;129-136.
18. Zimmerman H.J. Hepatotoxicity: the adverse effect of drugs and other chemicals on the liver. 2nd edition:1999;Lippincott Williams and Wilkins, Philadelphia.
19. Lewis J.H., Zimmerman H.J., Benson G.D.et al. NSAID-induced hepatotoxicity. Clin Liver Dis. 2:1998;543-561.
20. Desmet V.J. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol. 26(Suppl 1):1997;31-35.
21. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc. 73:1998;285-291.
22. Woolf G.M., Vierling J.M. Disappearing intrahepatic bile ducts: the syndrome and their mechanisms. Semin Liver Dis. 13:1993;261-275.
23. Ludwig J., Kim C.H., Wiesner R.H.et al. Floxuridine-induced sclerosing cholangitis: on ischemic cholangiopathy. Hepatology. 9:1989;215-218.
24. Castellano G., Moreno-Sanchez D., Guitierrez J.et al. Caustic sclerosing cholangitis. Report of four cases and a cumulative review of the literature. Hepatogastroenterology. 41:1994;458-470.
25. Zimmerman H.J., Lewis J.H. Chemical- and toxin-induced hepatotoxicity. Gastroenterol Clin N Am. 24:1995;1027-1045.
26. Clare N.T. Photosensitivity diseases in New Zealand. New Zealand Journal of Agricultural Research. 2:1959;1249.
27. Worker N.A., Dodd D.C. Photosensitivity disease in New Zealand. New Zealand Journal of Agricultural Research. 3:1960;212.
28. Arias I.M. Effects of plant acid (icterogenin) and certain anabolic steroids on the hepatic metabolism of bilirubin and sulfbromophthalein. Ann N Y Acad Sci. 104:1963;1014-1025.
29. Bullock G., Eakins M.N., Sawyer B.C.et al. Studies on bile duct secretion with the aid of the isolated perfused liver. Inhibitory action of sporidesmin and ictrogenin. Proceedings of the Royal Academy (London). 186:1974;333-336.
30. Philips M.J., Poucell S., Oda M. Biology of disease: mechanics of cholestasis. Lab Invest. 54:1977;593-608.
31. Ishizaki K., Kinbara S., Miyazawa N.et al. The biochemical studies on phalloidin-induced cholestasis in rats. Toxicol Lett. 90:1997;29-34.
32. Enat R., Pollack S., Ben-Arieh Y.et al. Cholestatic jaundice caused by cloxacillin: macrophage inhibition factor test in preventing rechallenge with hepatotoxic drugs. BMJ. 280:1980;982-983.
33. Utili R., Abernathy C.O., Zimmerman H.J. Cholestatic effects of Escherichia coli endotoxin on the isolated perfused rat liver. Gastroenterology. 70:1976;248-253.
34. Utili R., Abernathy C.O., Aaron S.A.et al. Cholestatic effects of Escherichia coli endotoxin on the sulfobromophthalein clearance in guinea pig. Experiencia. 33:1977;1631-1632.
35. Whiting J.F., Green R.M., Rosenbluth A.B.et al. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology. 22:1995;1233.
36. Zajicek G., Shamir R., Nordenberg J.et al. Increased turnover of intrahepatic bile ducts induced by bromobenzene. Dig Dis Sci. 40:1995;730-733.
37. Capelle P., Dhumeaux D., Mora M.et al. Effect of rifampacin on liver function in man. Gut. 13:1972;366-371.
38. Sutherland J.M., Keller W.H. Novobiocin and neonatal hyperbilirubinemia. Am J Dis Child. 101:1961;447.
39. Olamu A.B., Vicker C.R., Waring R.H.et al. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med. 318:1988;1089.
40. Palmer R. The hepatobiliary system: fundamental and pathological mechanism. Taylor W. Toxic effects of lithocholate on the liver and biliary disease. 1975;227-243 Plenum Press, New York.
41. Javitt N.B., Emerman S. Effect of sodium taurolithocholate on bile flow and bile acid excretion. J Clin Invest. 47:1968;1002.
42. Kopleman H., Scheuer P., Williams R. The liver lesion in Epping jaundice. QJM. 35:1966;553-564.
43. Bastian P.G. Occupational hepatitis caused by methylene dianiline. Med J Aust. 141:1984;533-535.
44. Mullick F.G., Ishak K.G., Mahabir R.et al. Hepatic injury associated with paraquat toicity in humans. Liver. 1:1981;209-221.
45. Kanz M.F., Wang A., Campbell G.A. Infusion of bile from methylene dianiline-treated rats into the common bile duct injures epithelial cells of recipient rats. Toxicol Lett. 78:1995;165.
46. Solis-Herruzo J.A., Castellano G., Colina F.et al. Hepatic injury in the toxic epidemic syndrome caused by the ingestion of adulterated cooking oil (Spain 1981). Hepatology. 4:1984;131-139.
47. Bloomer J.R., Zaccaria J., Klatskin G. Inhibitory effect of scillaren and dinitrophenol on bilirubin excretion of the isolated perfused liver. Proc Soc Exp Biol Med. 151:1976;539.
48. Ottenberg R., Spiegel R. The present status of non-obstructive jaundice due to infections and chemical agents.Causative agents, pathogenesis, innnnterrelationship, clinical characteristics. Medicine. 22:1943;17-27.
49. Yao F., Behling C.A., Saab S.et al. Trimethoprim-sulfamethoxazole- induced vanishing bile duct syndrome. Am J Gastroenterol. 92:1997;167-169.
50. Goldfarb S., Singer K., Popper H. Experimental cholangitis due to alpha-naphtylisothiocyanate (ANIT). Am J Pathol. 40:1962;685-695.
51. McLean M.R., Rees K.R. Hyperplasia of bile ducts induced by alpha nephthythiocyanate: experimental biliary cirrhosis free from biliary obstruction. J Pathol Bacteriol. 76:1958;175-188.
52. Alam I., Ferrell L.D., Bass N.M. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol. 91:1996;1626-1630.
53. Daisley H., Hutchinson G. Paraquat poisoning. Lancet. 352:1998;1393-1394.
54. Conradi S.E., Olanoff L.S., Dawson W.T. Jr. Fatality due to paraquat intoxication: confirmation by post-mortem tissue analysis. Am J Clin Pathol. 80:1983;771-776.
55. Witzleben C.H. Physiologic and morphologic natural history of a model of intrahepatic cholestasis (manganese-bilirubin overload). Am J Pathol. 66:1972;577.
56. Chiprut R.O., Viteri A., Jamroz C.et al. Intrahepatic cholestasis after griseofulvin administration. Gastroenterology. 70:1976;1141-1143.
57. Lavrijsen A.P., Balmus K.J., Nugteren-Huying W.M.et al. Liver damage during administration of itraconazole (Trisporal). Ned Tijdschr Geneeskd. 137:1993;38-41.
58. Lewis J.H., Zimmerman H.J., Benson G.D.et al. Hepatic injury associated with ketoconazole therapy. Gastroenterology. 86:1984;503-513.
59. Fernandes N.F., Gellere S.A., Fong T.L. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gatroenterol. 93:1998;459-460.
60. Manivel J.C., Bloomer J.R., Snover D.C. Progressive bile duct injury after thiabendazole administration. Gastroenterology. 93:1987;245-249.
61. Rex D., Lumeng L., Eble J.et al. Intrahepatic cholestasis and sicca complex after thiabendazole: report of a case and a review of the literature. Gastroenterology. 85:1983;718-721.
62. Chandruptala S., Demetris A.J., Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci. 47:2002;2186-2188.
63. Suriawinata A., Min A.D. A 33 year-old woman with jaundice after azithromycin use. Semin Liver Dis. 22(2):2002;207-210.
64. Fox J.C., Szykowski R.S., Sanderson S.O.et al. Progressive cholestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol. 42(6):2002;676-680.
65. Diehl A.M., Latham P., Boitnott J.K.et al. Cholestatic hepatitis from erythromycin ethylsuccinate: report of 2 cases. Am J Med. 76:1984;931-934.
66. Gholson C.F., Warren G.H. Fulminant liver failure associated with intravenous erythromycin lactobionate. Arch Intern Med. 150:1990;215-216.
67. Labowitz J.K., Silverman W.B. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci. 42:1997;192-194.
68. Levinson J.R., Kumar A. Ciprofloxacin-induced cholestatic jaundice: a case report. Am J Gastroenterol. 88:1993;1619.
69. Lucena M.I., Andrade R.J., Sanchez-Martinez H.et al. Norfloxacin-induced cholestatic jaundice [letter]. Am J Gastroenterol. 93:1998;2309-2311.
70. Hautekeete M.L., Kocks M.M., Naegels S.et al. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol. 23:1995;759-763.
71. Garcia Rodriguez L.A., Stricker B.H., Zimmerman H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 156:1996;1327-1332.
72. Larrey D., Vial T., Micaleff A.et al. Hepatitis associated with amoxicillin-clavulanic acid combination: report of 15 cases. Gut. 33:1992;368-371.
73. Brown S.J., Desmond P.V. Hepatotoxicity of antimicrobial agents. Semin Liver Dis. 22:2002;157-167.
74. Reddy K.R., Schiff E.R. Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Gastroenterol Clin N Am. 24:1995;923-926.
75. Westphal J.F., Vetter D., Brogard J.M. Hepatic side-effects of antibiotics. J Antimicrob Chemother. 33:1994;387-401.
76. Bjornsson E., Lindberg J., Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol. 32:1997;390-395.
77. Hunt C.M., Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology. 107:1994;1844-1847.
78. Altman C., Biour M., Grange J.D. Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases. Presse Med. 22:1993;1212-1216.
79. Dinscoy H.P., Saelinger D.A. Haloperidol-induced chronic liver disease. Gastroenterology. 83:1982;694-700.
80. Lok A.S.F., Ng I.O.L. Prochlorperazine-induced chronic cholestasis. J Hepatol. 6:1988;369-373.
81. Krebs S., Dorman H., Muth-Selbach U.et al. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol. 13:2001;67-69.
82. Horst D.A., Grace N.D., LeComte P.M. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology. 80:1980;550-554.
83. Randeva H.S., Bangar V., Sailesh S.et al. Fatal cholestatic jaundice associated with amitriptyline. Int J Clin Pract. 54(6):2000;405-406.
84. Galan-Navarro J.L. Acute cholestatic hepatitis probably caused by sertaline. Rev Esp Enferm Dig. 93(12):2001;822.
85. Taggart H.M., Alderice J.M. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. BMJ. 284:1982;1372.
86. Chitturi S., Farrell G.C. Drug induced cholestasis. Semin Gastrointest Dis. 12(2):2001;113-124.
87. Nachimuthu S., Volfinazon L., Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J. 77:2001;548-550.
88. Favreau M., Tannebaum H., Lough J. Hepatotoxicity associated with gold therapy. Ann Intern Med. 87:1977;717-719.
89. Srivastava M., Perez-Atayde A., Jonas M.M. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology. 115:1998;743-746.
90. Gierer I.M., Abdala O., Calderon C.et al. Meloxican-induced cholestasis. Acta Gastrenterollogica Latinoamericana. 30(5):2000;511-514.
91. Chitturi S., George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 22:2002;169-183.
92. Tarazi E.M., Harter J.G., Zimmerman H.J.et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology. 104:1993;569-574.
93. Schattner A., Kozak N., Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci. 322(4):2001;236-240.
94. Willens H.J. Clopidrogel-induced mixed hepatocellular and cholestatic injury. Am J Ther. 7(5):2000;317-318.
95. Manfredini R., Boari B., Regoli F.et al. Cholestatic liver reaction and heparin therapy. Arch Intern Med. 160(20):2000;3166.
96. Olsson R. Leonhardt. Cholestatic liver reaction during heparin therapy. J Intern Med. 229(5):1991;471-473.
97. Nunes A.C., Amaro P., Macas F.et al. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur J Gastroenterol Hepatol. 13(3):2001;279-282.
98. Andrade R.J., Lucena M.I., Fernandez M.C.et al. Cholestatic hepatitis related to the use of irbesartan: a case report and a review of angiotensin antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol. 14(8):2002;887-890.
99. Tsai M.H., Tsai S.L., Chen T.C., Liaw Y.F. Ticlopidine-induced cholestatic hepatitis with anti nuclear antibody in serum. J Formos Med Assoc. 99(11):2000;866-869.
100. Chaudrhry S., Oelsner D. Cholestatic reaction to warfarin [letter]. Am J Gastroenterol. 90:1995;853.
101. Depinho R.A., Goldberg C.S., Lefkowich J.H. Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology. 86:1984;162-165.
102. Klintmalm G.B.F., Iwatzuki S., Sterzl T.E. Cyclosporine A hepatotoxicity in 66 renal allograft recipients. Transplantation. 32:1981;488-489.
103. King P.D., Perry M.C. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin N Am. 24:1995;969-990.
104. Bashir R.M., Lewis J.H. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Gastroenterology Clinics of North America. 24:1995;963-967.
105. Jimenez-Saenz M., Arguelles-Arias F., Herrerias-Gutierrez.J.M.et al. Acute cholestatic hepatitis in a child treated with famotidine. Am J Gastroenterol. 95(12):2000;3665-3666.
106. Liberopoulas E.N., Nonni A.B., Tsianos E.V.et al. Possible ranitidine-induced cholestatic jaundice. Ann Pharmacother. 36(1):2002;172.
107. Sitruk V., Mohib S., Grando-Lemaire V.et al. Acute cholestatic hepatitis induced by glimepiride. Gastroenterol Clin Biol. 24(12):2000;1233-1234.
108. Desilets D.J., Shorr A.F., Moran K.A.et al. Cholestatic jaundice associated with the use of metformin. Am J Gastroenterol. 96(7):2001;2257-2258.
109. Pinto A.G., Cummings O.W., Chalasani N. Severe reversible cholestatic liver injury after pioglitazone therapy [letter]. Ann Intern Med. 137:2002;857.
110. Bonkovsky H.L., Azar R., Bird S.et al. Severe cholestatic hepatitis caused by thiazolidinediones. Dig Dis Sci. 47:2002;1632-1637.
111. Gregory D.M., Zaki G.F., Sarosis G.A.et al. Chronic cholestasis following prolonged tolbutamide administration. Arch Pathol. 84:1967;194-201.
112. Gitlin N., Julie N.L., Spurr C.L.et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 129:1998;36-38.
113. Torres M., Sobrino J., Asensia C.et al. Acute cholestasis induced by cervistatin. Spanish Medicina Clinica. 118(18):2002;717.
114. Batey R.G., Harvey M. Cholestasis associated with the use of pravastatin sodium. Med J Aust. 176(11):2002;561.
115. Habscheid W., Abele U., Dahm H.H. Severe cholestasis with kidney failure from anabolic steroids in a body builder. Dtsch Med Wochenschr. 124(36):1999;1029-1032.
116. Kreiss C., Amin S., Nalesnik M.A.et al. Severe cholestatic hepatitis in a patient taking acitretin. Am J Gastroenterol. 97(3):2002;775-776.
117. Sommers L.M., Schoene R.B. Allopurinol hypersensitivity syndrome associated with pancratic exocrine abnormalities and new onset diabetes-mellitus. Arch Intern Med. 162:2002;1190-1192.
118. Graffin H., Genty I., Cretel E.et al. Beta-carotene-induced hepatic fibrosis. Dig Dis Sci. 47:2002;93.
119. Veggi L.M., Crocenzi F.A., Roma M.G.et al. Dapsone-induced cholestasis and impairment of bile salt output in the rat. Biochem Pharmacol. 63(8):2002;1553-1563.
120. Stedman C. Herbal hepatotoxicity. Semin Liver Dis. 22(2):2002;195-206.
121. Stoschus B., Meybehm M., Spengler U.et al. Cholestasis associated with mesalamine therapy in a patient with Crohn's disease. J Hepatol. 26:1997;425-428.
122. Mondardini A., Pasquino P., Bernardi P.et al. Propafenone-induced liver injury: report of a case and review of the literature. Gastroenterology. 104:1993;1524-1526.
123. Bassendine M.F., Woodhouse K.W., Bennett M.et al. Dextropropoxyphene induced hepatotoxicity mimicking biliary tract disease. Gut. 27:1986;444-449.
124. Sanchez-Campos S., Lopez-Acebo R., Gonzalez P.et al. Cholestasis and alterations of gluthione metabolism induced by tacrolimus (FK506) in the rat. Transplantation. 66(1):1998;84-88.
125. Sahai A., Villeneuve J.P. Terfenadine-induced cholestatic hepatitis. Lancet. 348:1996;552-553.
126. Boyer B.A., Flemming C.R., Ludwig J.et al. Does long-term home parenteral nutrition in adults cause chronic liver disease. J Parenter Enteral Nutr. 9:1985;11-17.
127. Carson J.L., Strom B.L., Duff A.et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 119:1993;576-583.
128. Siegmund J.B., Tarrhis A.M. Prolonged jaundice after dicloxacillin therapy [letter]. Am J Gastroenterol. 88:1993;1299-1300.
129. Farmer G.D., Hoffman H.N., Shorter R.G.et al. Intrahepatic cholestasis associated with ingestion of erythromycin estolate (Ilosone). Gastroenterology. 45:1963;157-160.
130. Tolman M., Sannella J.J., Freston J.W. Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med. 81:1974;58-60.
131. Australian Drug Evaluation Committee The erythromycins: a further report from the Australian Drug Evaluation Committee. Med J Aust. 2:1973;192-193.
132. Brown R.A. Two cases of untoward reaction after 'Ilosone'. BMJ. 2:1963;913-914.
133. Zafrani E.S., Ishak K.G., Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of 9 cases. Dig Dis Sci. 24:1979;385-396.
134. Zimmerman H.J., Abernathy C.O. Employment of in vitro models for study of drug toxicity: application to phenothiazine related compounds and erythromycins. Brunner H., Thaler H. A Festschrift for Hans Popper. 1985;61-74 Raven Press, New York.
135. Keeffe E.B., Reis T.C., Berland J.E. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci. 27:1982;701-704.
136. Zeiger R.S., Schatz M., Sperling W.et al. Efficacy of troleandomycin in outpatients with severe corticosteroid-dependent asthma. J Allergy Clin Immunol. 66:1980;438-446.
137. Longo G., Valenti C., Gandini G.et al. Azithromycin-induced intrahepatic cholestasis. Am J Med. 102:1997;217-218.
138. Macaigne G., Mokbel M., Marty O.et al. Acute pseudoangicholitic hepatitis induced by azithromycin. Gastroenterol Clin Biol. 24:2000;969-970.
139. Pedersen F.M., Bathum L., Fenger C. Acute hepatitis and roxithromycin. Lancet. 341:1993;251-252.
140. Wallace R.J. Jr., Brown B.A., Griffith D.E. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 16:1993;215-221.
141. Lalak N.J., Morris D.L. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 25:1993;370-373.
142. Eckstein R.P., Dousett J.F., Lunzer M.R. Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy. Pathology. 25:1993;223-228.
143. Bolzan H., Spatoloa J., Castelletto T.et al. Intrahepatic cholestasis induced by amoxicillin alone. Gastroenterol Hepatol. 23:2000;237-239.
144. Reddy K.R., Brilliant P., Schiff E.R. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology. 96:1989;1135-1141.
145. Striker B.H., Van den Broek J.W., Keuning J.et al. Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (Augmentin). Dig Dis Sci. 34:1989;1576-1580.
146. Ragg M. Augmentin. Lancet. 2:1993;487.
147. Gauffre A., Mircheva J., Glotz D.et al. Autoantibodies against a kidney-liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis. Nephrol Dial Transplant. 12:1997;1961-1962.
148. Bataille L., Rahier J., Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long term ciprofloxacin therapy for Crohn's disease. J Hepatol. 37:2002;696-699.
149. Lazaros G.A., Paptheodoridis G.V., Delladetsima J.K.et al. Terbinafine-induced cholestatic liver disease. J Hepatol. 24:1996;753-756.
150. Mallat A., Zafrani E.S., Metreau J.M.et al. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci. 42:1997;1486-1488.
151. Tonder M., Nordoy A. Elgjo. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol. 9:1974;93-96.
152. Alberti-Flor J.J., Hernandez M.E., Ferrer J.P.et al. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole- trimethoprim. Am J Gastroenterol. 84:1989;1577-1579.
153. Palmer R.H. Bile acids, liver injury, and liver diseases. Arch Intern Med. 130:1972;606.
154. Cribb A.E. Adverse reaction to sulfonomide-trimethoprim. Adverse drug reaction toxicology review. 15:1996;49-50.
155. Montanaro A. A sulfonamide allergy. Immunol Allergy Clin N Am. 18:1998;843-849.
156. vanderVen A.J., Vree T.B., Koopmans P.P.et al. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. J Antimicrob Chemother. 37:1996;55-60.
157. Medina I., Mills J., Leoung G.et al. Oral therapy for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 323:1990;776-782.
158. Altraif I., Lilly L., Wanless I.R.et al. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim sulfamethaxazole. Am J Gastroenterol. 89:1994;1230-1234.
159. Kowdley K.V., Keeffe E.B., Fawaz K.A. Prolonged cholestasis due to trimethoprim-sulfamethoxazole. Gastroenterology. 102:1992;2148-2150.
160. Goldstein L.I., Ishak K.G., Burns W. Hepatic injury associated with nitrofurantoin therapy. Am J Dig Dis. 19:1974;987-998.
161. Sharp J.R., Ishak K.G., Zimmerman H.J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 92:1980;14-19.
162. Bagatell C.J., Bremmer W.J. Andogens in men-uses and abuses. N Engl J Med. 334:1996;707-714.
163. Tuchweber B., Weber A., Roy C.et al. Mechanisms of experimentally induced intrahepatic cholestasis. N Engl J Med. 339:1986;1217-1227.
164. Singh C., Bishop P., Wilson R. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements and ethanol: response to ursodeoxycholic acid treatment. Am J Gastroenterol. 91:1996;783-785.
165. Selye H. On the toxicity of estrogens with special reference to diethylstilbestrol. Can Med Assoc J. 41:1939;48-49.
166. Aldercreutx H., Ikonen G. Oral contraceptive and their damage. BMJ. 2(1133):1964;1133.
167. Holt C., Csete M. Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroenterol Clin N Am. 24:1995;853-874.
168. Simon F.R. Drug-induced cholestasis: pathology and clinical features. Clin Liver Dis. 2:1998;483-499.
169. Schreiber A.H., Simon F.R. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology. 3:1983;607-613.
170. Kern F. Jr., Erfling W., Simon F.R.et al. Effects of estrogen on the liver. Gastroenterology. 24:1978;969-990.
171. Hartley R.A., Boitnott J.K., Iber F.L. The liver and oral contraceptives. Johns Hopkins Med J. 124:1969;112-118.
172. Watson R.G.P., Olomu A., Clements D.et al. A proposed mechanism for cholorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol. 7:1988;72-78.
173. Zimmerman H.J. Updates on hepatotoxicity due to classes of drugs in common clinical use: nonsteroidal drugs, anti-inflammatory drugs, antibiotics, anti-hypertensives, cardiac and psychotropic agents. Semin Liver Dis. 10:1990;322-338.
174. Forbes G.M., Jeffrey G.P., Shilkin K.B.et al. Carbamezapine hepatotoxicity: another cause of vanishing bile duct syndrome. Gastroenterology. 102:1992;1785-1788.
175. Cosme A., Barrio J., Lobo C.et al. Acute cholestasis by fluoxetine [letter]. Am J Gastroenterol. 91:1996;2449-2450.
176. Lereche A., Vyberg M., Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (Clinoril). Histopathology. 11:1987;647.
177. Banks A.T., Zimmerman H.J., Ishak K.G.et al. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration. Hepatology. 22:1995;820.
178. Purcell P., Henry D., Melville G. Diclofenac hepatitis. Gut. 32:1991;1381.
179. O'Bierne J.P., Cairns S.R. Cholestatic hepatitis in association with celecoxib. Postgrad Med J. 77:2001;548-550.
180. Lilly J.R., Hitch D.C., Javitt N.B. Cimetidine cholestatic jaundice in children. J Surg Res. 24:1978;384-387.
181. Ramrakhiani S., Brunt E.M., Bacon B.R. Possible cholestatic injury from ranitidine with review of the literature. Am J Gastroenterol. 93:1998;822-826.
182. Kowdley K.V., Keeffe E.B. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am. 24:1995;2148-2150.
183. Kassianides C., Nursenblatt R., Palestine A.G.et al. Liver injury from cyclosporine A. Dig Dis Sci. 35:1990;693.
184. Bramow S., Ott P., Thomasen N.et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol. 89(3):2001;133-139.
185. Menard D.B., Gisselbrecht C., Marty M.et al. Antineoplastic agents and the liver. Gastroenterology. 78:1980;142-164.
186. Quigley E.M.M., Marsh M.N., Schaffner J.L.et al. Hepatobiliary complications of total parenteral nutrition. Gastroenterology. 104:1993;286-301.
187. Bashir R.M., Lipman T.O. Hepatobiliary toxicity of total parenteral nutrition in adults. Gastroenterol Clin N Am. 24:1995;1003-1025.
188. Cooper A., Betts S.M., Periera G.R.et al. Taurine deficiency in the severe hepatic dysfunction complicating total parenteral nutrition. Pediatr Res. 19:1984;462.
189. Stanko R.T., Nathan G., Mendelow H.et al. Development of hepatic cholestasis and fibrosis in patients with massive loss of intestine supported parenteral nutrition. Gastroenterology. 92:1987;197.
190. Bengoa J.M., Rosenberg I.H. Pattern and prognosis of hepatic dysfunction during parenteral nutrition in inflamatory disease. Gastroenterology. 82:1982;1016-1021.
191. Kohlroser J., Mathai J., Reichheld J.et al. Hepatotoxicity due to troglitazone: report of two cases and adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 95:2000;272-276.
192. Lebovitz H.E. Differentiatin members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev. 118(Suppl 2):2002;S23-S29.
193. Lebovitz H.E., Kreider M., Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 25:2002;815-821.
194. Novak D., Lewis J.H. Drug-induced liver disease. Curr Opin Gastroenterol. 19:2003;203-215.
195. May L.D., Lefkowitch J.H., Kram M.T. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 136:2002;449-552.
196. Gisolf E.H., Dreezen C., Danner S.A.et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 31:2000;1234-1239.
197. Reisler K. High hepatotoxicity seen among HAART patients. Aids Alert. 16:2001;118-119.
198. Sulkowski M.S., Thomas D.L., Chaisson R.E.et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283:2000;74-80.
199. Gradon J.D., Chapnick E.K., Sepkowwitz D.V. Zidovudine-induced hepatitis. J Intern Med. 231:1992;317-318.
200. Freiman J.P., Helfert K.E., Hamrell M.R.et al. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 7:1993;379-385.
201. Olano J.P., Boruki M.J., Wen J.W.et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving Zidovudine. Clin Infect Dis. 21:1995;973-975.
202. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 20:1998;1071-1092.
203. Grieco A., Vecchio F.M., Geco A.V.et al. Cholestatic hepatitis due to ticlidopine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol. 10(8):1998;713-715.
204. Amaro P., Nunes A., Macoas F., Ministro B.et al. Ticlidopine-induced prolonged cholestasis: a case report. Eur J Gastroenterol Hepatol. 11(6):1999;673-676.
205. Rahmat J., Gelfand R.L., Gelfand M.C.et al. Captopril-associated cholestatic jaundice. Ann Intern Med. 101:1985;56-58.
206. Hanauer S.B. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. (Suppl 4):1999;16-22. discussion 38.
207. Menghini V.V., Arora A.S. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc. 76:2001;84-86.
208. Saleem G., Li S.C., MacPherson B.R. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy. Arthritis Rheum. 44:2001;1966-1968.
209. Marino G., Zimmerman H.J., Lewis J.H. Management of drug-induced liver disease. Curr Gastroenterol Rep. 3:2001;38-48.
210. O'Brien C.B., Shields D.S., Saul S.H.et al. Drug induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol. 91:1996;1456-1457.
211. Duerksen D.R., Van Aerde J.E., Gramlich L.et al. Intravenous ursodeoxycholic acid reduced cholestasis in parenterally fed newborn piglets. Gastroenterology. 111:1996;1111-1117.
212. Heuman D.M. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology. 104:1993;1865-1868.
213. Bergassa N.V., Alling D.W., Talbot T.L.et al. Effect of naloxone infusions in patients with the pruritus of cholestasis. Ann Intern Med. 123:1995;161-167.